Cevimeline

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Cevimeline
Cevimeline.svg
Cevimeline 3D.png
Clinical data
Trade names Evoxac
AHFS/Drugs.com Monograph
MedlinePlus a608025
Pregnancy
category
  • C
Routes of
administration
By mouth (capsules)
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding <20%
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
Formula C10H17NOS
Molar mass 199.31308 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Cevimeline (trade name Evoxac) is a parasympathomimetic and muscarinic agonist,[1] with particular effect on M1 and M3 receptors. It is used in the treatment of dry mouth and especially associated with Sjögren's syndrome.

Mechanism of action[edit]

By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.

Side effects[edit]

Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping.[2]

Contraindications include asthma and angle closure glaucoma.[citation needed]

See also[edit]

  • Pilocarpine — a similar parasympathomimetic medication for dry mouth (xerostomia)
  • Bethanechol — a similar muscarinic parasympathomimetic with longer-lasting effect

References[edit]

  1. ^ Ono M, Takamura E, Shinozaki K, et al. (July 2004). "Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study". Am. J. Ophthalmol. 138 (1): 6–17. doi:10.1016/j.ajo.2004.02.010. PMID 15234277. 
  2. ^ [1] MedicineNet: Cevimeline. Accessed 10/12/2007

External links[edit]